WAY-317538 (SEN-12333) is a drug that acts as a potent and selective
full agonist for the
α7 subtype of neural
nicotinic acetylcholine receptors. It was not the most potent compound in the series, but was selected for further development on the basis of its high selectivity over related receptors, ease of synthesis, and good in vivo properties including high oral bioavailability and good brain penetration.[1] It has
nootropic and
neuroprotective effects in animal studies, and is being investigated as a potential treatment for neurodegenerative and neurocognitive conditions including
Alzheimer's disease and
schizophrenia.[2]
References
^Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, et al. (July 2009). "SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist". Bioorganic & Medicinal Chemistry. 17 (14): 5247–58.
doi:
10.1016/j.bmc.2009.05.040.
PMID19515567.
^Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, et al. (May 2009). "Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 459–68.
doi:
10.1124/jpet.108.150094.
PMID19223665.
S2CID6667145.